A prospective study of iodine status, thyroid function, and prostate cancer risk: Follow-up of the first national health and nutrition examination survey

Nutrition and Cancer

Volumn 58, Issue 1, 2007, Pages 28-34

  Hoption Cann, Stephen A ^a   Qiu, Zhenguo ^b   Van Netten, Christiaan ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; IODINE;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; CREATININE URINE LEVEL; GOITER; HEALTH STATUS; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUTRITION; PROSPECTIVE STUDY; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; THYROID FUNCTION; UNITED STATES;

EID: 34447540132     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580701307960     Document Type: Article

References (68)

1. Bilek R, Gkonos PJ, Tavianini MA, Smyth DG, and Roos BA: The thyrotrophin-releasing hormone (TRH)-like peptides in rat prostate are not formed by expression of the TRH gene but are suppressed by thyroid hormone. J Endocrinol 132, 177-184, 1992.
2. Mani Maran RR, Subramanian S, Rajendiran G, Sunil N, Archunan G, et al.: Prostate-thyroid axis: stimulatory effects of ventral prostate secretions on thyroid function. Prostate 36, 8-13, 1998.
3. Esquenet M, Swinnen JV, Heyns W, Verhoeven G: Triiodothyronine modulates growth, secretory function and androgen receptor concentration in the prostatic carcinoma cell line LNCaP. Mol Cell Endocrinol 109, 105-11, 1995.
4. Zhang S, Hsieh ML, Zhu W, Klee GG, Tindall DJ, and Young CY: Interactive effects of triiodothyronine and androgens on prostate cell growth and gene expression. Endocrinology 140, 1665-1671, 1999.
5. Hsieh ML and Juang HH: Cell growth effects of triiodothyronine and expression of thyroid hormone receptor in prostate carcinoma cells. J Androl 26, 422-428, 2005.
6. Lehrer S, Diamond EJ, Stone NN, Droller MJ, and Stock RG: Serum triiodothyronine is increased in men with prostate cancer and benign prostatic hyperplasia. J Urol 168, 2431-2433, 2002.
7. Lehrer S, Diamond EJ, Stone NN, Droller MJ, Stock RG, Stone M, Bajwa A, and Kornreich R: Elevated serum triiodothyronine (t3) in Ashkenazi Jewish prostate cancer patients carrying the I1307k allele of the APC (adenopolyposis coli) gene. Urol Oncol 21, 101-104, 2003.
8. Delange FM: Iodine deficiency. In: Werner & Inbar's The Thyroid: A Fundamental and Clinical Text, 8th ed. Braverman LE and Utiger RD (eds.). Philadelphia: Lippincott-Williams & Wilkins, 295-316, 2000.
9. Key TJ, Silcocks PB, Davey GK, Appleby PN, and Bishop DT: A case-control study of diet and prostate cancer. Br J Cancer 76, 678-687, 1997.
10. Miller HW: National Center for Health Statistics: Plan and operation of the Health and Nutrition Examination Survey, 1971-1973. Vital Health Stat 1, 10a. Hyattsville, MD: US Department of Health, Education, and Welfare, 1973.
11. National Center for Health Statistics: National Center for Health Statistics: Plan and operation of the Health and Nutrition Examination Survey. 1971-1973. Vital Health Stat 1, 10b. Hyattsville, MD: US Department of Health, Education, and Welfare, 1977.
12. National Center for Health Statistics: National Center for Health Statistics: Plan and operation of the NHANES I Epidemiologic Follow-up Study. 1982-1984. Vital Health Stat 1, No. 22. Hyaltsville, MD: US Department of Health and Human Services, 1987.
13. National Center for Health Statistics: National Center for Health Statistics: Plan and operation of the NHANES I Epidemiologic Follow-up Study, 1986. Vital Health Stat 1, No. 25. Hyattsville, MD: US Department of Health and Human Services, 1990.
14. National Center for Health Statistics: National Center for Health Statistics: Plan and operation of the NHANES I Epidemiologic Follow-up Study, 1987. Vital Health Stat 1, No. 27. Hyattsville, MD: US Department of Health and Human Services, 1992.
15. Cox C, Mussolino ME, Rothwell ST, Lane MA, Golden CD, et al.: Plan and operation of the NHANES I Epidemiologic Follow-up Study. 1992. Vital Health Stat 1, No. 35. Hyattsville, MD: US Department of Health and Human Services, 1997.
16. Benotti J, Benotti N, Pino S, and Gardyna H: Determination of total iodine in urine, stool, diets, and tissue. Clin Chem 11, 932-936, 1965.
17. Korn EL, Graubard BI, and Midthune D: Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 145, 72-80, 1997.
18. Nagata K, Takasu N, Akamine H, Ohshiro C, Komiya I, et al.: Urinary iodine and thyroid antibodies in Okinawa, Yamagata, Hyogo, and Nagano, Japan: the differences in iodine intake do not affect thyroid antibody positivity. Endocr J 45, 797-803, 1998.
19. Konno N, Yuri K, Miura K, Kumagai M, and Murakami S: Clinical evaluation of the iodide/creatinine ratio of casual urine samples as an index of daily iodide excretion in a population study. Endocr J 40, 163-169, 1993.
20. Cann SA, van Netten JP, and van Netten C: Iodine, selenium and the development of breast cancer. Cancer Causes Control 11, 121-127, 2000.
21. International Agency for Research on Cancer: GLOBOCAN 2002 Database. http://www-dep.iarc.fr/
22. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, et al.: Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 63, 963-966, 1991.
23. Tominaga S and Kuroishi T: An ecological study on diet/nutrition and cancer in Japan. Int J Cancer Suppl 10, 2-6, 1997.
24. van Netten C, Hoption Cann SA, Morley DR, and van Netten JP: Elemental and radioactive analysis of commercially available seaweed. Sci Total Environ 255, 169-175, 2000.
25. Ohno Y, Yoshida O, Oishi K, Okada K, Yamabe H, et al.: Dietary beta-carotene and cancer of the prostate: a case-control study in Kyoto, Japan. Cancer Res 48, 1331-1336, 1988.
26. Allen NE, Sauvaget C, Roddam AW, Appleby P, Nagano J, et al.: A prospective study of diet and prostate cancer in Japanese men. Cancer Causes Control 15, 911-920, 2004.
27. Terry PD, Terry JB, and Rohan TE: Long chain (n-3) fatty acid intake and risk of cancers of the breast and the prostate: recent epidemiological studies, biological mechanisms, and directions for future research. J Nutr 134, 3412S-3420S, 2004.
28. Allen NE, Sauvaget C, Roddam AW, Appleby P, Nagano J, el al.: A prospective study of diet and prostate cancer in Japanese men. Cancer Causes Control 15, 911-920, 2004.
29. Sonoda T, Nagata Y, Mori M, Miyanaga N, and Takashima N: A ease-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci 95, 238-242, 2004.
30. Dugrillon A: lodolaetones and iodoaldehydes - mediators of iodine in thyroid autoregulation. Exp Clin Endocrinol Diabetes [Suppl] 104, 41-45, 1996.
31. 2) prevents cancer promotion. Mol Cell Endocrinol 236, 49-57. 2005.
32. Venturi S: Is there a role for iodine in breast diseases? Breast 10. 379-382, 2001.
33. Smyth PP: Role of iodine in antioxidant defence in thyroid and breast disease. Biofactors 19, 121-130, 2003.
34. 2-iodide cytotoxic system. J Exp Med 156, 1262-1267, 1982.
35. Majerus PM and Courtois PA: Susceptibility of Candida albicans to peroxidase-catalyzed oxidation products of thiocyanate, iodide and bromide. J Biol Buceale 20, 241-245, 1992.
36. Cann SA, van Netten JP, Glover DW, and van Netten C: Iodide accumulation in extrathyroidal tissues. J Clin Endocrinol Metab 84, 821-822, 1999.
37. Ihalin R, Loimaranta V, and Tenovuo J: Origin, structure, and biological activities of peroxidases in human saliva. Arch Biochem Biophys 445, 261-268, 2006.
38. Spitzweg C, Joba W, Eisenmenger W, and Heufelder AE: Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab 83, 1746-1751, 1998.
39. - symporter and Pendred syndrome gene protein expressions in human extra-thyroidal tissues. Eur J Endocrinol 144, 297-302, 2001.
40. Wapnir IL, van de Rijn M, Nowels K, Amenta PS, Walton K, et al.: Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab 88, 1880-1888, 2003.
41. Behrouzian R and Aghdami N: Urinary iodine/creatinine ratio in patients with stomach cancer in Urmia, Islamic Republic of Iran. East Mediterr Health J 10, 921-924, 2004.
42. Feldt-Rasmussen U: Iodine and cancer. Thyroid 11, 483-486, 2001
43. Venturi S, Donati FM, Venturi A, Venturi M, Grossi L, et al.: Role of iodine in evolution and carcinogenesis of thyroid, breast and stomach. Adv Clin Path 4, 11-17, 2000.
44. Ohshima M and Ward JM: Dietary iodine deficiency as a tumor promoter and carcinogen in male F344/NCr rats. Cancer Res 46, 877-883, 1986.
45. Fang WT, Qao BS, and Wang JB: Iodine deficiency induces thyroid cancer in rats and mice. Zhonghua Zhong Liu Za Zhi 16, 341-344, 1994.
46. Ronckers CM, McCarron P, and Ron E: Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer 117, 281-288, 2005.
47. Eskin BA: Iodine and mammary cancer. Adv Exp Med Biol 91, 293-304, 1977.
48. Eskin BA, Grotkowski CE, Connolly CP, and Ghent WR: Different tissue responses for iodine and iodide in rat thyroid and mammary glands. Biol Trace Elem Res 49, 9-19, 1995.
49. Funahashi H, Imai T, Tanaka Y, Tobinaga J, Wada M, et al.: Suppressive effect of iodine on DMBA-induced breast tumour growth in the rat. J Surg Oncol 61, 209-213, 1996.
50. Strum JM: Effect of iodide-deficiency on rat mammary gland. Virchows Arch [B] 30, 209-220, 1979.
51. Bobrov MI: The significance of micro-iodine therapy in preventing and treatment of mastopathy. Vestn Akad Med Nauk SSSR 24, 80-84, 1969.
52. Ghent WR, Eskin BA, Low DA, and Hill LP: Iodine replacement in fibrocystic disease of the breast. Can J Surg 36, 453-460, 1993.
53. Kessler JH: The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia. Breast J 10, 328-336, 2004.
54. Langer R, Burzler C, Bechtner G, and Gartner R: Influence of iodide and iodolactones on thyroid apoptosis. Evidence that apoptosis induced by iodide is mediated by iodolactones in intact porcine thyroid follicles. Exp Clin Endocrinol Diabetes 111, 325-329, 2003.
55. Dugrillon A and Gartner R: delta-Iodolactones decrease epidermal growth factor-induced proliferation and inositol-1,4,5-trisphosphate generation in porcine thyroid follicles - a possible mechanism of growth inhibition by iodide. Eur J Endocrinol 132, 735-743, 1995.
56. Dugrillon A, Uedelhoven WM, Pisarev MA, Bechtner G, and Gartner R: Identification of delta-iodolactonc in iodide treated human goiter and its inhibitory effect on proliferation of human thyroid follicles. Horm Metab Res 26, 465-469, 1994.
57. Pawlega J: Does salt protect against breast cancer? Nutr Cancer 12, 197-199, 1989.
58. Hollowell JG, Staehling NW, Hannon WH, Flanders DW, Gunter EW, et al.: Iodine nutrition in the United States. Trends and public health implications: iodine excretion data from National Health and Nutrition Examination Surveys I and III (1971-1974 and 1988-1994). J Clin Endocrinol Metab 83, 3401-3408, 1998.
59. Aleshin BV and Bondarenko LA: Role of the thyroid hormone in the functioning of the hypophyseal adrenal-gonad system of rabbits. Probl Endokrinol 30, 49-52, 1984.
60. th ed. Braverman LE and Utiger RD (eds.). Philadelphia: Lippincott-Williams & Wilkins, 467-473, 2000.
61. Kilbane MT, Ajjan RA, Weetman AP, Dwyer R, McDermott EW, et al.: Tissue iodine content and serum-mediated 125I uptake-blocking activity in breast cancer. J Clin Endocrinol Metab 85, 1245-1250, 2000.
62. Kuijpens JL, Nyklictek I, Louwman MW, Weetman TA, Pop VJ, et al.: Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid 15, 1253-1259, 2005.
63. Abnet CC, Fan JH, Kamangar F, Sun XD, Taylor PR, et al.: Self-reported goiter is associated with a significantly increased risk of gastric noncardia adenocarcinoma in a large population-based Chinese cohort. Int J Cancer 119, 1508-1510, 2006.
64. Kandemir EG, Yonem A, and Narin Y: Gastric carcinoma and thyroid status. J Int Med Res 33, 222-227, 2005.
65. Hoption Cann SA: Dietary iodine intake in the etiology of cardiovascular disease. J Am Coll Nutr 25, 1-11, 2006.
66. Haberkorn U, Kinscherf R, Kissel M, Kubler W, Mahmut M, et al.: Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose. Gene Ther 10, 774-780, 2003.
67. Mitrofanova E, Unfer R, Vahanian N, Daniels W, Roberson E, et al.: Rat sodium iodide symporter for radioiodide therapy of cancer. Clin Cancer Res 10, 6969-6976, 2004.
68. Zhang L, Sharma S, Zhu LX, Kogai T, Hershman JM, et al.: Nonradioactive iodide effectively induces apoptosis in genetically modified lung cancer cells. Cancer Res 63, 5065-5072, 2003.